Pulsenmore revenue ralies to NIS6 million

• Pulsenmore reported first half 2026 revenue of NIS 6.1 million, up 53% year over year.
• The company launched U.S. commercialization after FDA authorization and signed its first U.S. provider agreements.
• Pulsenmore raised NIS 22.5 million and ended June with NIS 70 million in cash and short-term deposits.

Pulsenmore (NASDAQ:PLSM) reported first half 2026 revenue of NIS 6.1 million, approximately $2 million, up 53% year over year, with gross profit also increasing 53% to NIS 2.2 million.

The results came as the company expanded commercialization activities following FDA authorization, while operating expenses increased 4% to NIS 23 million and operating loss remained broadly stable at NIS 20.8 million.

Pulsenmore reported total comprehensive loss of NIS 35 million, up 51% year over year, mainly due to higher net financial expenses of NIS 14.3 million, while the company sold approximately 4,265 devices and secured ES Tera regulatory clearances.

Pulsenmore raised NIS 22.5 million, approximately $7.5 million, through a private placement and ended June 30, 2026 with NIS 70 million, approximately $23.4 million, in cash, cash equivalents, and short-term deposits.

Pulsenmore develops remote healthcare monitoring technologies, including home-based ultrasound solutions designed to support medical providers and patients.

The company expanded partnerships in Israel and the United States and received NIS 5 million, approximately $1.67 million, in artificial intelligence grants to support continued technology development.